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Sir
We welcome the comments of Speirs and her co-workers concern-
ing the variation and expression of ERb protein in breast cancer
tissues as reported by ourselves (Saunders et al, 2002a) and Skliris
et al (2001). Clearly, the differences may be caused by variations in
sensitivity or speciﬁcity of the assays, or both, and it will be impor-
tant to pinpoint the reason. If sensitivity (and the methodology
which might lead to this is discussed below), then discrepancies
may be resolved by determining appropriate cut-off values. On
the other hand, differences in speciﬁcity may produce variations
that are not simply related to ERb expression. It may therefore
be useful to add the following perspective.
In our laboratory we have used a polyclonal antibody raised
to hinge domain of ERb for several studies on human tissues
(Critchley et al, 2001; Saunders et al, 2000). When this antibody
was tested on breast tissue sections we detected expression of
nuclear receptor in most sections within both normal and
cancerous cells (unpublished observations). In 1998 two papers
were published showing that several isoforms of ERb can be
encoded by mRNAs formed by alternative splicing at the 3'
end of the gene (Moore et al, 1998; Ogawa et al, 1998). Further-
more, Ogawa et al (1998) showed that the protein of one of
these forms (Erbcx/ERb2), that lacks the ability to bind oestra-
diol, could be detected in tissue culture cells following
transfection and could blunt the response to oestrogen if co-
expressed with ERa. Because the peptide used to raise our poly-
clonal antibody could recognise both the wildtype ERb and this
variant isoform we repeated our studies on breast tissue using a
monoclonal antibody raised against the C terminus of full-length
ERb1 (Saunders et al, 2002a) which we have shown does not
cross react with ERbcx/ERb2 (Saunders et al, 2002b). Although
the biological signiﬁcance of the expression of ERb variant
proteins is not known it is notable that expression of ERbcx
has been reported to occur in prostatic cancers (Fujimura et
al, 2001) and we have detected expression in breast cancer
biopsies (Saunders, Miller manuscript in preparation). Immuno-
histochemical evaluations based on antibodies the speciﬁcity of
which is not well deﬁned may therefore lead to mis-interpreta-
tion of the likelihood that a tissue will respond to oestrogens
via full-length ERb.
In our experience there are two other factors that can have an
adverse affect on the quality and reliability of detection of ERb
protein namely tissue ﬁxation and the speciﬁcity of secondary
antibodies. Based on our experiences we believe poor tissue preser-
vation (e.g. underﬁxation seen in the centre of large tissue
fragments) and even over ﬁxation (cross-linking of epitopes) can
account for some of the variation in the detection of ERb reported
over the last few years. Western analyses can also be problematic.
We have found that ERb breaks down readily in solution and
cannot withstand more than one freeze–thaw cycle, furthermore
several secondary antibodies we have tried have given false positive
bands, some with molecular weights close to ERb, when tested on
membranes without the addition of primary antibody.
Taking all these factors into account it is perhaps unsurprising
that we are some way from deciding how the detection of ERb
should inﬂuence decisions regarding the oestrogenic responsiveness
of tissues including the breast (and it is worth noting that the
application of ERa required years of reﬁnement). However, we
are currently assessing the predictive value of our assay for ERb
in tumours from patients with breast cancer receiving neo-adjuvant
treatment with tamoxifen.
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